Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 07 01:54PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-3.22 Insider Own69.75% Shs Outstand33.82M Perf Week51.08%
Market Cap1.06B Forward P/E- EPS next Y-2.31 Insider Trans0.00% Shs Float12.36M Perf Month49.69%
Income-113.77M PEG- EPS next Q-0.59 Inst Own21.82% Short Float / Ratio0.06% / 0.11 Perf Quarter22.53%
Sales0.00M P/S- EPS this Y1.54% Inst Trans-0.13% Short Interest0.01M Perf Half Y188.90%
Book/sh3.96 P/B6.57 EPS next Y4.06% ROA-60.17% Target Price30.96 Perf Year1144.05%
Cash/sh4.10 P/C6.34 EPS next 5Y20.59% ROE-66.24% 52W Range2.13 - 29.80 Perf YTD131.12%
Dividend- P/FCF- EPS past 5Y- ROI-70.13% 52W High-12.75% Beta-3.32
Dividend %- Quick Ratio10.46 Sales past 5Y0.00% Gross Margin- 52W Low1120.69% ATR1.89
Employees65 Current Ratio10.46 Sales Q/Q- Oper. Margin0.00% RSI (14)76.54 Volatility12.23% 8.42%
OptionableNo Debt/Eq0.00 EPS Q/Q-148.12% Profit Margin- Rel Volume5.75 Prev Close24.75
ShortableYes LT Debt/Eq0.00 EarningsNov 02 BMO Payout- Avg Volume75.57K Price26.00
Recom1.43 SMA2048.26% SMA5042.24% SMA20084.08% Volume300,985 Change5.05%
Date Action Analyst Rating Change Price Target Change
Sep-25-23Initiated Wedbush Outperform $27
Aug-15-23Upgrade Morgan Stanley Equal-Weight → Overweight $10 → $34
Oct-05-22Initiated Bryan Garnier Buy $16
Sep-13-22Resumed JMP Securities Mkt Outperform $34 → $18
Aug-23-22Downgrade Morgan Stanley Overweight → Equal-Weight $40 → $10
Aug-22-22Downgrade BofA Securities Neutral → Underperform $26 → $13
May-25-22Initiated JMP Securities Mkt Outperform $34
Mar-02-21Initiated SVB Leerink Outperform $50
Mar-02-21Initiated Oppenheimer Outperform $48
Mar-02-21Initiated Morgan Stanley Overweight $51
Dec-06-23 10:16AM
06:50AM Loading…
Nov-30-23 06:50AM
Nov-15-23 06:50AM
Nov-09-23 11:00AM
Nov-02-23 06:50AM
Oct-30-23 06:50AM
Oct-13-23 06:50AM
Oct-04-23 07:34AM
Sep-19-23 06:50AM
Sep-06-23 06:51AM
08:09PM Loading…
Aug-31-23 08:09PM
Aug-23-23 06:50AM
Aug-15-23 09:59AM
Aug-07-23 06:50AM
Jul-21-23 10:20AM
Jul-03-23 08:16AM
Jun-27-23 12:11PM
Jun-26-23 02:27PM
Jun-20-23 06:50AM
Jun-10-23 06:01PM
Jun-01-23 06:50AM
May-17-23 09:55AM
May-08-23 06:50AM
May-06-23 01:00PM
06:51AM Loading…
Apr-05-23 06:51AM
Mar-20-23 03:31PM
Mar-18-23 12:35AM
Mar-02-23 06:50AM
Feb-24-23 06:50AM
Feb-08-23 06:50AM
Jan-24-23 05:36AM
Jan-09-23 06:50AM
Dec-08-22 01:15PM
Nov-10-22 08:00AM
Oct-11-22 02:27PM
Oct-07-22 08:30AM
Sep-30-22 06:50AM
Sep-16-22 04:45AM
Sep-12-22 06:50AM
Aug-22-22 04:09PM
Jul-14-22 08:10AM
Jul-06-22 08:10AM
Jun-14-22 08:10AM
Jun-07-22 08:10AM
May-16-22 08:10AM
May-11-22 08:15AM
May-05-22 04:10PM
May-04-22 01:14PM
Apr-06-22 04:10PM
Mar-29-22 08:10AM
Mar-22-22 08:10AM
Mar-03-22 08:00AM
Feb-25-22 09:40AM
Feb-09-22 08:10AM
Jan-26-22 09:40AM
Dec-22-21 08:10AM
Dec-07-21 08:10AM
Nov-10-21 08:10AM
Nov-08-21 05:51AM
Nov-02-21 02:00PM
Sep-03-21 08:00AM
Jul-30-21 08:00AM
Jul-09-21 06:10PM
Jul-01-21 07:00AM
Jun-11-21 08:00AM
Jun-04-21 03:45AM
May-26-21 08:00AM
May-12-21 07:00AM
May-06-21 06:58AM
Apr-29-21 04:15PM
Apr-21-21 08:00AM
Mar-04-21 08:00AM
Feb-26-21 08:00AM
Feb-19-21 10:00AM
Feb-09-21 04:05PM
Feb-04-21 08:08PM
Pharvaris NV operates as a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of innovative therapies for rare diseases focused on angioedema and other bradykinin-mediated diseases. Its PHA121 program is designed to treat all sub-types of hereditary angioedema. The company was founded by Luc Dochez, Jens Schneider-Mergener, Berndt A. E. Modig, Jochen Knolle, Hans Gerardus Christiaan Petrus Schikan, and Anne Lesage on September 30, 2015 and is headquartered in Leiden, the Netherlands.